Stanley-Laman Group’s AbbVie ABBV Stock Holding History

Stanley-Laman Group’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-1,525	Closed	-$283K	–	252
2025 Q2	$283K	Sell	1,525 -567	-27%	-$105K	0.04%	243
2025 Q1	$438K	Hold	2,092	–	–	0.07%	206
2024 Q4	$372K	Hold	2,092	–	–	0.05%	227
2024 Q3	$413K	Buy	2,092 +22	+1%	+$4.11K	0.06%	223
2024 Q2	$355K	Hold	2,070	–	–	0.05%	226
2024 Q1	$377K	Hold	2,070	–	–	0.05%	206
2023 Q4	$321K	Hold	2,070	–	–	0.05%	202
2023 Q3	$309K	Sell	2,070 -25,379	-92%	-$3.73M	0.05%	200
2023 Q2	$3.7M	Sell	27,449 -2,165	-7%	-$317K	0.61%	64
2023 Q1	$4.72M	Sell	29,614 -585	-2%	-$89.4K	0.84%	29
2022 Q4	$4.88M	Sell	30,199 -698	-2%	-$107K	0.93%	25
2022 Q3	$4.15M	Buy	30,897 +639	+2%	+$91.7K	0.79%	31
2022 Q2	$4.63M	Buy	30,258 +1,075	+4%	+$164K	0.82%	29
2022 Q1	$4.73M	Buy	29,183 +1,566	+6%	+$227K	0.66%	38
2021 Q4	$3.74M	Buy	27,617 +3,103	+13%	+$367K	0.44%	64
2021 Q3	$2.64M	Buy	24,514 +1,938	+9%	+$221K	0.34%	77
2021 Q2	$2.54M	Buy	22,576 +2,585	+13%	+$291K	0.36%	77
2021 Q1	$2.16M	Sell	19,991 -96	-0.5%	-$10.3K	0.36%	78
2020 Q4	$2.15M	Buy	20,087 +5,189	+35%	+$499K	0.38%	65
2020 Q3	$1.3M	Sell	14,898 -551	-4%	-$51.9K	0.29%	98
2020 Q2	$1.52M	Buy	15,449 +3,281	+27%	+$289K	0.36%	67
2020 Q1	$927K	Sell	12,168 -2,157	-15%	-$184K	0.28%	102
2019 Q4	$1.27M	Sell	14,325 -921	-6%	-$76.5K	0.3%	104
2019 Q3	$1.15M	Sell	15,246 -192	-1%	-$13.2K	0.28%	109
2019 Q2	$1.12M	Sell	15,438 -406	-3%	-$31.9K	0.27%	117
2019 Q1	$1.28M	Sell	15,844 -3,304	-17%	-$270K	0.31%	93
2018 Q4	$1.76M	Sell	19,148 -1,426	-7%	-$125K	0.49%	61
2018 Q3	$1.95M	Sell	20,574 -387	-2%	-$36.7K	0.48%	66
2018 Q2	$1.94M	Buy	20,961 +856	+4%	+$83.6K	0.44%	71
2018 Q1	$1.9M	Sell	20,105 -2,596	-11%	-$285K	0.43%	74
2017 Q4	$2.19M	Sell	22,701 -80	-0.4%	-$7.54K	0.47%	70
2017 Q3	$2.02M	Buy	22,781 +1,076	+5%	+$81.9K	0.54%	72
2017 Q2	$1.57M	Buy	21,705 +490	+2%	+$32.9K	0.43%	78
2017 Q1	$1.38M	Buy	21,215 +7,769	+58%	+$488K	0.37%	88
2016 Q4	$842K	Sell	13,446 -150,959	-92%	-$9.21M	0.26%	122
2016 Q3	$10.4M	Buy	164,405 +151,272	+1,152%	+$9.79M	4.24%	2
2016 Q2	$813K	Sell	13,133 -20,457	-61%	-$1.25M	0.32%	125
2016 Q1	$1.92M	Sell	33,590 -57,270	-63%	-$3.19M	0.36%	60
2015 Q4	$5.38M	Buy	90,860 +80,321	+762%	+$4.63M	0.92%	30
2015 Q3	$573K	Sell	10,539 -1,042	-9%	-$67.8K	0.12%	180
2015 Q2	$778K	Buy	11,581 +2,160	+23%	+$141K	0.14%	165
2015 Q1	$552K	Sell	9,421 -2,587	-22%	-$156K	0.1%	205
2014 Q4	$786K	Buy	12,008 +1,982	+20%	+$125K	0.15%	156
2014 Q3	$579K	Buy	10,026 +100	+1%	+$5.55K	0.11%	185
2014 Q2	$560K	Sell	9,926 -694	-7%	-$36.4K	0.1%	194
2014 Q1	$546K	Buy	10,620 +5,281	+99%	+$267K	0.1%	188
2013 Q4	$282K	Buy	+5,339	New	+$262K	0.06%	177

Other funds holding ABBV

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Stanley-Laman Group's ABBV Position: Q3 2025 in Review

Stanley-Laman Group sold out of AbbVie (ABBV) in Q3 2025, closing a stake of 1,525 shares — an estimated $283K sold.

Stanley-Laman Group first reported a position in ABBV in Q4 2013 and held it in 47 quarters. The position peaked at $10.4M in Q3 2016. 3,905 funds tracked by Wall St. Rank hold ABBV as of Q3 2025.

Stanley-Laman Group reported no remaining AbbVie position as of Q3 2025 after selling out during the quarter.
Stanley-Laman Group sold 1,525 AbbVie shares in Q3 2025, an estimated $283K.
Stanley-Laman Group first reported a position in AbbVie in Q4 2013 and held it in 47 quarters.
Stanley-Laman Group's AbbVie position peaked at $10.4M in Q3 2016.
3,905 funds tracked by Wall St. Rank held AbbVie as of Q3 2025.

Based on Stanley-Laman Group's 13F filing for Q3 2025, filed 22 Oct 2025.